Myriad RBM Inc.
http://www.myraidrbm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myriad RBM Inc.
Making The Most Of A Maturing Myriad Genetics
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.
Deals Shaping The Medical Industry, September 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Company Information
- Industry
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- EDI GmbH
- Psynova Neurotech Limited
- Rules-Based Medicine, Inc